| Application | Recommended Dilution |
|---|---|
| ELISA | 1:5000-1:50000 |
| FC | 1:50-1:200 |
CD69 serves as one of the earliest cell surface markers of lymphocyte activation, appearing within hours of stimulation on T cells, B cells, natural killer cells, and other immune cell populations. As a C-type lectin receptor, CD69 plays important regulatory roles in immune cell trafficking, retention in tissues, and modulation of inflammatory responses, making it an essential marker for researchers studying immune activation dynamics, tissue-resident lymphocyte biology, and inflammatory disease mechanisms.
This recombinant monoclonal antibody, clone 30H2, offers the reproducibility and consistency that demanding immunological studies require. Generated through recombinant expression technology with a defined human IgG4(S228P) isotype, this antibody eliminates the lot-to-lot variability inherent in traditional hybridoma production, ensuring your experimental results remain comparable across extended research timelines and multi-site collaborations.
Validation studies demonstrate robust performance across multiple detection platforms. In functional ELISA assays, the antibody exhibits strong binding to immobilized human CD69 protein with an EC50 of 23.17–26.04 ng/mL, confirming high-affinity target recognition suitable for quantitative applications at dilutions ranging from 1:5000 to 1:50000. Flow cytometry validation using CHO-K1 cells stably transfected with human CD69 shows clear discrimination between CD69-expressing and untransfected control populations, supporting its utility for activation phenotyping studies at recommended dilutions of 1:50 to 1:200.
Whether you are characterizing early activation events in primary human lymphocytes, investigating tissue-resident memory cell populations, or exploring CD69's emerging roles in stem cell biology, this affinity-purified antibody provides a reliable tool for advancing your immunological research.
Email: support@cusabio.com
Distributors Worldwide